Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Company is investing more than €100 million in the expansion of the Halle site
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
Subscribe To Our Newsletter & Stay Updated
